Abstract
Background Modern literature has brought into question if wear of tibial inserts made from conventional or highly-crosslinked polyethylene (HXL PE) is still a factor limiting longevity of total knee arthroplasty (TKA) in the mid- to long-term. It is the objective of this study to determine: 1) most common causes of mid- to long-term TKA failure, 2) the prevalence of delamination, and 3) the medial/lateral linear wear rates of conventional and HXL PE tibial inserts retrieved in the mid- to long-term.
Methods A tibial insert retrieval cohort of 107 inserts (79 conventional, 28 HXL PE) with a minimum time in situ of 6.5 years (mean 11.7±4) was studied. Failure causes were determined from chart-review, delamination presence was assessed microscopically, and medial/lateral linear wear was determined by minimal thickness changes measured with a dial-indicator.
Results The most common mid-to long-term etiologies for failure were instability (44.9%), PE wear 15%), aseptic loosening (14%) and infection (13.1%). Delamination occurred in 70% of inserts (72.1% conventional, 64.3% HXLPE). Gross material loss due to delamination appeared to be the underlying reason for at least 33.3% of cases exhibiting instability. Of the cases removed for infection, 75% exhibited no histopathological hallmarks of acute infection. The medial/lateral wear rates were 0.054/0.051 (conventional) and 0.014/0.011 (HXL) mm/year, respectively.
Conclusions Polyethylene wear still appears to be a major primary and secondary cause for TKA revision in the mid- to long-term. Wear may manifest as destabilizing delamination or as continuous release of fine wear particles potentially resulting in inflammatory responses and subsequent failure.
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at ww.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work; HJL has received research support from Zimmer Biomet and has committee appointments for Orthopaedic Research Society, DWVC has received research support from DePuy Synthes Joint Reconstruction, Medacta, Inc., and Granite Medical, and has received other financial or material support form Total Joint Orthopedics, JJJ does consultancy for Medtronic Sofamor Danek, has stock or stock options from Implant Protection, receives research support from Medtronic Sofamor Danek, Nuvasive, and Zimmer Biomet, BRL receives royalties from Link, does consultancy for Link, Enovis, and Zimmer Biomet, has stock or stock options from Pfizer, receives royalties, financial or material support from Human Kinetics, Wolters Kluwer, Elsevier, and Slack Inc, is a member of editorial/governing boards for Journal of Arthroplasty, Arthroplasty Today (Deputy Editor), and Orthopedics, and has committee appointments for American Association of Hip and Knee Surgeons, American Association of Orthopaedic Surgeons, Mid-America Orthopaedic Association, Hip Society, and Knee Society; no other relationships or activities that could appear to have influenced the submitted work.
Funding Statement
This study was partially funded by an internal pilot grant from Rush University (Rush Catalyst Award, PIs Lundberg and Pourzal).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Rush University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Numbers in the first two paragraphs updated with minor changes.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
